Skip to main content
. 2015 Sep 28;34(6):2864–2870. doi: 10.3892/or.2015.4314

Figure 5.

Figure 5

Lapatinib upregulated HER2 expression and enhanced trastuzumab-mediated antibody-dependent cellular cytotoxicity in malignant pleural mesothelioma cell lines. (A) NCI-H28 and (B) NCI-H2052 cells were treated with DMSO or 1 µM of afatinib or lapatinib for 24 h, then the binding site of trastuzumab was analyzed using FITC-conjugated trastuzumab. FITC-conjugate rituximab was used as an isotype control. Representative data of three independent experiments are shown. (C) NCI-H28 and (D) NCI-H2052 cells were treated with DMSO or 1 µM of lapatinib or afatinib for 24 h, then trastuzumab-mediated antibody-dependent cellular cytotoxicity (ADCC) was assessed using the LDH release assay. Representative data of three independent experiments (MPM cell lines) are shown. The values are presented as the mean ± SD of triplicate samples. E:T ratio; effector/target ratio. *p<0.05 vs. E: Ef + Tra, T: DMSO, #p<0.01 vs. E: Ef + Rit, T: Lap; Two-way ANOVA followed by Bonferroni's post test.